Michael D Privitera, MD

Medical Degree: SUNY Upstate Medical University Syracuse, NY,

Bachelor of Arts: The Johns Hopkins University Baltimore, 1976 (Biology)

Residency: Georgetown University Washington, DC, 1984 (Neurology)

Fellowship: University of Texas Southwestern Medical Center Dallas, TX, 1986 (Clinical Neurophysiology in Epilepsy)

American Board of Psychiatry and Neurology (Neurology) (Certification Date: 04-30-1987 )

Clinical Neuropsychology

Epilepsy

Neurology

Absence Seizures (Petit Mal Seizures)

Anti-Epileptic Drug Toxicity

Atonic Seizures

Clonic seizures

Complex Partial Seizure

Epilepsia Partialis Continua

Epilepsy in Pregnancy

Epilepsy-Related Cognitive Dysfunction

Febrile Seizure

Focal Seizures

Frontal Lobe Seizures

Generalized Epilepsy

Generalized Seizure

Genetic Epilepsy

Grand Mal Seizures

Juvenile Myoclonic Epilepsy

Landau-Kleffner Syndrome

Myoclonic Seizures

Myoclonus

Nonconvulsive Status Epilepticus

Partial Motor Epilepsy

Partial Seizure

Partial Sensory Epilepsy

Post-Traumatic Epilepsy

Progressive Myoclonic Epilepsies

Psychogenic Seizure

Referred Pain

Reflex Epilepsy

Rolandic Epilepsy

Seizure Disorders

Seizures

Severe Seizures

Status Epilepticus

Temporal Lobe Seizure

Tonic Seizures

Tonic-Clonic Seizure (Grand mal seizure)

Unverricht-Lundborg Syndrome

Epilepsy

Neurology

Epilepsy; Antiepileptic Drug Pharmacology and Kinetics; Antiepileptic Drug Development; Clinical Trials; Surgical Treatment of Epilepsy; Epilepsy Genetics; Seizure Disorders; Electroencephalogram (EEG)

- Jan/1987-Aug/1993 Assistant Professor, Department of Neurology, University of Cincinnati College of Medicine ,

- Sept/1993-Aug/1998 Associate Professor (with tenure), Department of Neurology, University of Cincinnati College of Medicine ,

- Jan/1993-1998 Consultant, Jewish Hospital, Cincinnati, OH,

- Jan/1987-Oct/2002 Director of EEG Laboratory and Epilepsy Monitoring Unit, University Hospital (accredited by American EEG Society, 1993) ,

- Jan/1987-2003 Director, Clinical Neurophysiology/Epilepsy Fellowship Program (accredited by American Board Psychiatry and Neurology, 1997) ,

- Apr/2003-July/2004 Assistant Dean Practice Plan, University of Cincinnati Medical Center,

- Jan/1997-present Consultant in Neurology, The Christ Hospital,

- Jan/1987-present Consultant in Neurology, VA Medical Center, Cincinnati, OH ,

- Jan/1987-present Director, Cincinnati Epilepsy Center,

- Jul/1993-present Consultant, Cincinnati Children’s Hospital, Cincinnati, OH,

- Sep/1998-present Professor (with tenure), Department of Neurology,

- Sep/2000-June 2008 Medical Director and Chair of Clinical Practice and Research Committees, UC Physicians,

- Apr/2000-Jan 2008 Vice-President, University Neurology, Inc.,

- Apr/2000-Jan 2008 Vice-Chair, Administrative and Clinical, Department of Neurology,

- Oct 2004-present Clinical Leadership Council of University Hospital,

- Jan 2005–2006 Interim Director of Waddell MS Center, University of Cincinnati,

- Jan 2005-2008 Board of Trustees of the American Epilepsy Society,

- July 2008- present Treasurer, American Epilepsy Society,

2000 to present Co-Investigator: Quality of Life in Newly Diagnosed Epilepsy and Seizures. Mentored Patient-Oriented Research Career Development Award (K23), National Institutes of Health.

2000 to present Site Principal Investigator: Neurodevelopment Effects of Antiepileptic Drugs. National Institutes of Health.

2002 to present Co-Investigator: Talampanel as adjunctive therapy in patients with partial seizures. Ivax Laboratories.

2003 to present Principal Investigator: SP615: An open-label extension trial to determine the tolerability and efficacy of long-term oral SPM 927 as adjunctive therapy in patients with partial seizures. Schwarz Pharma.

2005 – present An open-label extension trial to determine safety and efficacy of long-term oral SPM 927 in patients with partial seizures.

2006 to present Co-Investigator: Linking serotonin function in MDMA users by concurrent EEG and fMRI (NIH K01)

2006 to present Co-Mentor: EEG-fMRI in patients with JME (NIH K23 NS052468). Mentored Patient-Oriented Research Career Development Award (K23), National Institutes of Health. Award period: 7/1/06-6/30/11; Budget $875,552

2007-present Co-Investigator A international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (≥ 16 to 70 years old_ with Partial Onset Seizures PI David Ficker, MD

2008 – present Co-Investigator: An open-label multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy PI David Ficker, MD

2008 - present A double-blind, placebo-controlled, dose-escalation, parallel-group study to evaluate the efficacy and safety of E207 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures (Eisai Clinical Study Protocol E2007-G000-304)

2008- present A 14-month open-label extension phase of the double-blind, placebo-controlled, dose-escalation, parallel-group studies to evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures (Eisai Clinical Study Protocol E2007-G000-307)

2008- present Co-Investigator: Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome, UCB $60,150. PI: David Ficker, M.D.

2008 - Present Co-Investigator: Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox-Gastaut Syndrome. PI: David Ficker, M.D.

Grant: #SRS 001803 Investigators:Privitera, Michael 07-01-2005 -06-30-2008 American Epilepsy Society, Inc. A Multicenter Consortium to Plan and Execute a Randomized Clinical Trial Exploring Medication Resistance in Newly Diagnosed Epilepsy Role:PI $60,000.00 Active Level:Private Non-Profit

Grant: #R01 NS038455 Investigators:Privitera, Michael 09-01-2005 -08-31-2010 National Institute of Neurological Disorders and Stroke Neurodevelopment Effects of Antiepileptic Drugs in Humans (NEAD II) Role:PI $251,258.80 Active Level:Federal

Grant: #1-R01-NS-40396-03-A0-S1-E0 Investigators:Privitera, Michael 01-01-2004 -12-31-2004 National Institute of Neurological Disorders and Stroke Genetic Influences on Human Epilepsy Role:PI $30,500.00 Closed Level:Federal

Grant: #5-R01-NS-38455-05-A0-S0-E0 Investigators:Privitera, Michael 09-30-2000 -08-31-2005 National Institute of Neurological Disorders and Stroke Neurodevelopment Effects of Antiepileptic Drugs in Humans Role:PI $135,346.00 Closed Level:Federal

Investigators:Privitera, Michael 01-01-2002 -12-07-2002 University of Cincinnati Neuroscience Institute Blood Genomics of Seisures & Syncope Role:PI $20,000.00 Closed Level:Industry

Grant: #5-N01-NS-72374-03-A0-S0-E0 Investigators:Privitera, Michael 08-01-1997 -10-31-1999 National Institute of Neurological Disorders and Stroke Losigamone as Monotherapy in the Treatment of Complex Partial Seizures Role:PI $298,649.00 Closed Level:Federal

Grant: #SRS 006284 Investigators:Privitera, Michael 06-01-2008 -08-31-2009 National Institute of Neurological Disorders and Stroke Progesterone Therapy for Women with Epilepsy Role:PI $3,642.00 Active Level:Federal

Grant: #INTREPID - 2566 Study / W81XWH-09-1-0496 Investigators:Privitera, Michael; Szaflarski, Jerzy 04-01-2011 -03-31-2013 Department of Defense A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI) ... (INTREPID-2566 Study) Role:PI $336,852.00 Active Level:Federal

Grant: #SRS 007808 Investigators:Privitera, Michael 09-16-2011 -09-15-2014 Food and Drug Administration EQUIGEN Generic Equivalence Trials Role:PI $1,595,332.00 Active Level:Federal

Grant: #Fellowship - Bonner Investigators:Bonner, Shawna; Privitera, Michael; Shear, Paula 08-01-2012 -10-31-2012 Epilepsy Foundation Social Cognition and Psychosocial Functioning in Temporal Lobe Epilepsy Role:Collaborator $3,000.00 Closed Level:Private Non-Profit

Grant: #S980286 \ NS038455 Investigators:Flood-Shaffer, Kellie; Privitera, Michael 08-01-2012 -07-31-2017 National Institute of Neurological Disorders and Stroke Maternal Outcomes and Neurodevelopment Effects of Antiepileptic Drugs (MONEAD) Role:PI $80,963.00 Awarded Level:Federal

Grant: #134275 / 5R01NS035929 Investigators:Privitera, Michael 01-01-2014 -12-31-2014 National Institute of Neurological Disorders and Stroke Presurgical Applications of FMRI in Epilepsy Role:PI $10,965.63 Active Level:Federal

Grant: #ECHO sub CDC 1NU58DP006256-02-00 Investigators:Privitera, Michael 06-01-2018 -05-31-2019 Centers for Disease Control and Prevention Project ECHO Role:PI $100,000.00 Awarded Level:Federal

Grant: #S02583-01 / 5 U48 DP006389-02 Investigators:Privitera, Michael 08-01-2021 -09-29-2021 Centers for Disease Control and Prevention University of Iowa Prevention Research Center for Rural Health Role:PI 0.00 Hold Level:Federal

Grant: #Project ECHO - New 5 year segment Investigators:Privitera, Michael 09-30-2021 -09-29-2026 Centers for Disease Control and Prevention Project ECHO - New 5 year segment Role:PI 116114.40 Hold Level:Federal

Investigators:Privitera, Michael 01-28-2022 -01-27-2025 Neurelis An Exploratory Open-Label Study of the Effects on Responsive Neurostimulator EEG Epileptiform Activity After Intranasal Administration of a Single Dose of Valtoco to People with Epilepsy... Role:PI 181124.21 Hold Level:Industry

Grant: #EQU-202 12-01-2022 -11-30-2025 Medpace Inc. A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures Role:PI 0.00 Hold Level:Industry

Grant: #EQU-202 12-01-2022 -11-30-2025 Medpace Inc. A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures Role:PI 0.00 Hold Level:Industry

Grant: #pending Investigators:Privitera, Michael 09-30-2023 -09-29-2024 Centers for Disease Control and Prevention Expanding epilepsy self-management support in healthcare networks (EXPAND) Role:PI 849280.11 Hold Level:Federal

12-19-2023 -12-19-2026 Neurava Inc. A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions Role:PI 92268.99 Hold Level:Industry

12-19-2023 -12-19-2026 Neurava Inc. A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions Role:PI 92268.99 Hold Level:Industry

Grant: #BHV7000-302 03-04-2024 -03-05-2027 Biohaven Therapeutics, Ltd. A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy Role:PI 228327.36 Hold Level:Industry

Grant: #BHV7000-302 03-04-2024 -03-05-2027 Biohaven Therapeutics, Ltd. A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy Role:PI 228327.36 Hold Level:Industry

Grant: #BHV7000-201 10-01-2024 -10-01-2027 Biohaven Therapeutics, Ltd. A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy Role:PI 326135.95 Active Level:Industry

Grant: #BHV7000-201 10-01-2024 -10-01-2027 Biohaven Therapeutics, Ltd. A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy Role:PI 326135.95 Active Level:Industry

Peer Reviewed Publications

Buelow,J. M., Privitera,M., Levisohn,P., Barkley,G. L.  (2009). A description of current practice in epilepsy monitoring units. Epilepsy & behavior : E&B, 15 (3) , 308-313

McNally,K. A., Schefft,B. K., Szaflarski,J. P., Howe,S. R., Yeh,H. S., Privitera,M. D.  (2009). Application of signal detection theory to verbal memory testing to distinguish patients with psychogenic nonepileptic seizures from patients with epileptic seizures. Epilepsy & behavior : E&B, 14 (4) , 597-603

Meador,K. J., Baker,G. A., Browning,N., Clayton-Smith,J., Combs-Cantrell,D. T., Cohen,M., Kalayjian,L. A., Kanner,A., Liporace,J. D., Pennell,P. B., Privitera,M., Loring,D. W., NEAD Study Group  (2009). Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England journal of medicine, 360 (16) , 1597-1605

Incorpora,G., Pavone,P., Cocuzza,M., Privitera,M., Pavone,L., Ruggieri,M.  (2009). Neonatal onset of bath-induced alternating hemiplegia of childhood. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

Potter,J. L., Schefft,B. K., Beebe,D. W., Howe,S. R., Yeh,H. S., Privitera,M. D.  (2009). Presurgical neuropsychological testing predicts cognitive and seizure outcomes after anterior temporal lobectomy. Epilepsy & behavior : E&B, 16 (2) , 246-253

Fargo,J. D., Schefft,B. K., Szaflarski,J. P., Howe,S. R., Yeh,H. S., Privitera,M. D.  (2008). Accuracy of clinical neuropsychological versus statistical prediction in the classification of seizure types. The Clinical neuropsychologist, 22 (2) , 181-194

Szaflarski,J. P., Holland,S. K., Jacola,L. M., Lindsell,C., Privitera,M. D., Szaflarski,M.  (2008). Comprehensive presurgical functional MRI language evaluation in adult patients with epilepsy. Epilepsy & behavior : E&B, 12 (1) , 74-83

Privitera,M. D.  (2008). Generic antiepileptic drugs: current controversies and future directions. Epilepsy currents / American Epilepsy Society, 8 (5) , 113-117

Ramirez,M. J., Schefft,B. K., Howe,S. R., Hwa-Shain,Y., Privitera,M. D.  (2008). Interictal and postictal language testing accurately lateralizes language dominant temporal lobe complex partial seizures. Epilepsia, 49 (1) , 22-32

Vannest,J., Szaflarski,J. P., Privitera,M. D., Schefft,B. K., Holland,S. K.  (2008). Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy & behavior : E&B, 12 (3) , 410-418

Incorpora,G., Pavone,P., Ruggieri,M., Cocuzza,M., Mazzone,L., Parano,E., Privitera,M.  (2008). Neonatal onset of hot water reflex seizures in monozygotic twins subsequently manifesting episodes of alternating hemiplegia. Epilepsy research, 78 (2-3) , 225-231

Griffith,N. M., Smith,K. M., Schefft,B. K., Szaflarski,J. P., Privitera,M. D.  (2008). Optimism, pessimism, and neuropsychological performance across semiology-based subtypes of psychogenic nonepileptic seizures. Epilepsy & behavior : E&B, 13 (3) , 478-484

Schefft,B. K., Dulay,M. F., Fargo,J. D., Szaflarski,J. P., Yeh,H. S., Privitera,M. D.  (2008). The use of self-generation procedures facilitates verbal memory in individuals with seizure disorders. Epilepsy & behavior : E&B, 13 (1) , 162-168

Szaflarski,J. P., Meckler,J. M., Szaflarski,M., Shutter,L. A., Privitera,M. D., Yates,S. L.  (2007). Levetiracetam use in critically ill patients. Neurocritical care, 7 (2) , 140-147

Testa,S. M., Schefft,B. K., Szaflarski,J. P., Yeh,H. S., Privitera,M. D.  (2007). Mood, personality, and health-related quality of life in epileptic and psychogenic seizure disorders. Epilepsia, 48 (5) , 973-982

Griffith,N. M., Szaflarski,J. P., Schefft,B. K., Isaradisaikul,D., Meckler,J. M., McNally,K. A., Privitera,M. D.  (2007). Relationship between semiology of psychogenic nonepileptic seizures and Minnesota Multiphasic Personality Inventory profile. Epilepsy & behavior : E&B, 11 (1) , 105-111

Fargo,J. D., Schefft,B. K., Kent,G. P., Szaflarski,J. P., Privitera,M. D., Yeh,H. S.  (2007). The prevalence of seizure types among individuals referred for phase I neuropsychological assessment: demographic and neuropsychological characteristics. The Clinical neuropsychologist, 21 (3) , 442-455

Chadwick,D., Privitera,M.  (2006). How skeptical should we be about industry-sponsored studies?. Neurology, 67 (3) , 378-379

Privitera,M.  (2006). Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry. Epilepsy research, 68 (1) , 52-56

Szaflarski,M., Meckler,J. M., Privitera,M. D., Szaflarski,J. P.  (2006). Quality of life in medication-resistant epilepsy: the effects of patient';s age, age at seizure onset, and disease duration. Epilepsy & behavior : E&B, 8 (3) , 547-551

Szaflarski,M., Szaflarski,J. P., Privitera,M. D., Ficker,D. M., Horner,R. D.  (2006). Racial/ethnic disparities in the treatment of epilepsy: what do we know? What do we need to know?. Epilepsy & behavior : E&B, 9 (2) , 243-264

Welty,T. E., Faught,E., Privitera,M. D.  (2006). Step therapy is not appropriate for antiepileptic drugs. Journal of managed care pharmacy : JMCP, 12 (3) , 269-70; author reply 270-1

Kent,G. P., Schefft,B. K., Howe,S. R., Szaflarski,J. P., Yeh,H. S., Privitera,M. D.  (2006). The effects of duration of intractable epilepsy on memory function. Epilepsy & behavior : E&B, 9 (3) , 469-477

Fargo,J. D., Schefft,B. K., Dulay,M. F., Privitera,M. D., Yeh,H. S.  (2005). Confrontation naming in individuals with temporal lobe epilepsy: a quantitative analysis of paraphasic error subtypes. Neuropsychology, 19 (5) , 603-611

Ficker,D. M., Privitera,M., Krauss,G., Kanner,A., Moore,J. L., Glauser,T.  (2005). Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology, 65 (4) , 593-595

Griffith,N. M., Szaflarski,J. P., Szaflarski,M., Kent,G. P., Schefft,B. K., Howe,S. R., Privitera,M. D.  (2005). Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II. Epilepsy & behavior : E&B, 7 (2) , 266-272

Arroyo,S., Dodson,W. E., Privitera,M. D., Glauser,T. A., Naritoku,D. K., Dlugos,D. J., Wang,S., Schwabe,S. K., Twyman,R. E., EPMN-106/INT-28 Investigators  (2005). Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurologica Scandinavica, 112 (4) , 214-222

Goldberg-Stern,H., Gadoth,N., Ficker,D., Privitera,M.  (2005). The effect of age and structural lesions on postictal language impairment. Seizure : the journal of the British Epilepsy Association, 14 (1) , 62-65

Fargo,J. D., Schefft,B. K., Szaflarski,J. P., Dulay,M. F., Testa,S. M., Privitera,M. D., Yeh,H. S.  (2004). Accuracy of self-reported neuropsychological functioning in individuals with epileptic or psychogenic nonepileptic seizures. Epilepsy & behavior : E&B, 5 (2) , 143-150

Privitera,M., Ficker,D. M.  (2004). Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial. Epilepsy & behavior : E&B, 5 (6) , 841-846

Szaflarski,J. P., Holland,S. K., Schmithorst,V. J., Dunn,R. S., Privitera,M. D.  (2004). High-resolution functional MRI at 3T in healthy and epilepsy subjects: hippocampal activation with picture encoding task. Epilepsy & behavior : E&B, 5 (2) , 244-252

Tang,Y., Lu,A., Ran,R., Aronow,B. J., Schorry,E. K., Hopkin,R. J., Gilbert,D. L., Glauser,T. A., Hershey,A. D., Richtand,N. W., Privitera,M., Dalvi,A., Sahay,A., Szaflarski,J. P., Ficker,D. M., Ratner,N., Sharp,F. R.  (2004). Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1. Brain research.Molecular brain research, 132 (2) , 155-167

Goldberg-Stern,H., Gadoth,N., Cahill,W., Privitera,M.  (2004). Language dysfunction after frontal lobe partial seizures. Neurology, 62 (9) , 1637-1638

Cavitt,J., Privitera,M.  (2004). Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. Archives of Neurology, 61 (10) , 1604-1607

Privitera,M. D., Welty,T.  (2004). Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology, 62 (1) , 161; author reply 161

Dulay,M. F., Schefft,B. K., Fargo,J. D., Privitera,M. D., Yeh,H. S.  (2004). Severity of depressive symptoms, hippocampal sclerosis, auditory memory, and side of seizure focus in temporal lobe epilepsy. Epilepsy & behavior : E&B, 5 (4) , 522-531

Tang,Y., Glauser,T. A., Gilbert,D. L., Hershey,A. D., Privitera,M. D., Ficker,D. M., Szaflarski,J. P., Sharp,F. R.  (2004). Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurologica Scandinavica, 109 (3) , 159-168

Abou-Khalil,B., Hemdal,P., Privitera,M. D.  (2003). An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure : the journal of the British Epilepsy Association, 12 (3) , 141-149

Privitera,M. D.  (2003). Phase IV trials: a wolf in sheep';s clothing?. The Annals of Pharmacotherapy, 37 (5) , 741-743

Schefft,B. K., Marc Testa,S., Dulay,M. F., Privitera,M. D., Yeh,H. S.  (2003). Preoperative assessment of confrontation naming ability and interictal paraphasia production in unilateral temporal lobe epilepsy. Epilepsy & behavior : E&B, 4 (2) , 161-168

Szaflarski,J. P., Szaflarski,M., Hughes,C., Ficker,D. M., Cahill,W. T., Privitera,M. D.  (2003). Psychopathology and quality of life: psychogenic non-epileptic seizures versus epilepsy. Medical science monitor : international medical journal of experimental and clinical research, 9 (4) , CR113-8

Szaflarski,J. P., Hughes,C., Szaflarski,M., Ficker,D. M., Cahill,W. T., Li,M., Privitera,M. D.  (2003). Quality of life in psychogenic nonepileptic seizures. Epilepsia, 44 (2) , 236-242

Privitera,M. D., Brodie,M. J., Mattson,R. H., Chadwick,D. W., Neto,W., Wang,S., EPMN 105 Study Group  (2003). Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica, 107 (3) , 165-175

Welty,T. E., Gidal,B. E., Ficker,D. M., Privitera,M. D.  (2002). Levetiracetam: a different approach to the pharmacotherapy of epilepsy. The Annals of Pharmacotherapy, 36 (2) , 296-304

Privitera,M. D., Welty,T. E., Ficker,D. M., Welge,J.  (2002). Vagus nerve stimulation for partial seizures. Cochrane database of systematic reviews (Online), (1) (1) , CD002896

Dulay,M. F., Schefft,B. K., Testa,S. M., Fargo,J. D., Privitera,M., Yeh,H. S.  (2002). What does the family pictures subtest of the Wechsler Memory Scale-III measure? Insight gained from patients evaluated for epilepsy surgery. The Clinical neuropsychologist, 16 (4) , 452-462

Privitera,M.  (2001). Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia, 42 Suppl 4, 31-35

Chaisewikul,R., Privitera,M. D., Hutton,J. L., Marson,A. G.  (2001). Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane database of systematic reviews (Online), (1) (1) , CD001901

Marson,A. G., Hutton,J. L., Leach,J. P., Castillo,S., Schmidt,D., White,S., Chaisewikul,R., Privitera,M., Chadwick,D. W.  (2001). Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy research, 46 (3) , 259-270

Ficker,D. M., Shukla,R., Privitera,M. D.  (2001). Postictal language dysfunction in complex partial seizures: effect of contralateral ictal spread. Neurology, 56 (11) , 1590-1592

Privitera,M. D., Yeh,H. S., Blisard,K., Sanchez,N.  (2000). Detection of epileptogenic focal cortical dysplasia by depth, not subdural electrodes. Neurosurgical review, 23 (1) , 49-51

Morrell,M. J., McLean,M. J., Willmore,L. J., Privitera,M. D., Faught,R. E., Holmes,G. L., Magnus,L., Bernstein,P., Rose-Legatt  (2000). Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure : the journal of the British Epilepsy Association, 9 (4) , 241-248

Szaflarski,J. P., Ficker,D. M., Cahill,W. T., Privitera,M. D.  (2000). Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology, 55 (10) , 1561-1563

Akimura,T., Yeh,H. S., Mantil,J. C., Privitera,M. D., Gartner,M., Tomsick,T. A.  (1999). Cerebral metabolism of the remote area after epilepsy surgery. Neurologia medico-chirurgica, 39 (1) , 16-25; discussion 25-7

Privitera,M. D., Szaflarski,J. P.  (1999). Complex Partial Seizures in Adults. Current treatment options in neurology, 1 (4) , 323-338

Fleck,D. E., Berch,D. B., Shear,P. K., Schefft,B. K., Privitera,M. D., Strakowski,S. M.  (1999). Directed forgetting deficits in patients with temporal lobe epilepsy: an information processing perspective. Journal of the International Neuropsychological Society : JINS, 5 (6) , 549-555

Privitera,M. D.  (1999). Evidence-based medicine and antiepileptic drugs. Epilepsia, 40 Suppl 5, S47-56

Chadwick,D., Privitera,M.  (1999). Placebo-controlled studies in neurology: where do they stop?. Neurology, 52 (4) , 682-685

McLean,M. J., Morrell,M. J., Willmore,L. J., Privitera,M. D., Faught,R. E., Holmes,G. L., Magnus-Miller,L., Bernstein,P., Rose-Legatt,A.  (1999). Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia, 40 (7) , 965-972

Gidal,B. E., Privitera,M. D., Sheth,R. D., Gilman,J. T.  (1999). Vigabatrin: a novel therapy for seizure disorders. The Annals of Pharmacotherapy, 33 (12) , 1277-1286

Welty,T. E., Privitera,M., Shukla,R.  (1998). Increased seizure frequency associated with felbamate withdrawal in adults. Archives of Neurology, 55 (5) , 641-645

Warner,A., Privitera,M., Bates,D.  (1998). Standards of laboratory practice: antiepileptic drug monitoring. National Academy of Clinical Biochemistry. Clinical chemistry, 44 (5) , 1085-1095

Kaplan,M., Privitera,M.  (1997). Affective illness and epilepsy. The Journal of clinical psychiatry, 58 (11) , 498-499

Privitera,M.  (1997). Complex partial status epilepticus. Neurology, 48 (4) , 1140-1141

Rosenfeld,W. E., Sachdeo,R. C., Faught,R. E., Privitera,M.  (1997). Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia, 38 Suppl 1, S34-6

Privitera,M. D.  (1997). Topiramate: a new antiepileptic drug. The Annals of Pharmacotherapy, 31 (10) , 1164-1173

Privitera,M., Welty,T. E.  (1996). Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Archives of Neurology, 53 (11) , 1191-1192

Gidal,B. E., Wagner,M. L., Privitera,M. D., Dalmady-Israel,C., Crismon,M. L., Fagan,S. C., Graves,N. M.  (1996). Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. The Annals of Pharmacotherapy, 30 (11) , 1272-1276

Gidal,B. E., Crismon,M. L., Wagner,M. L., Fagan,S. C., Privitera,M. D., Dalmady-Israel,C., Graves,N. M.  (1996). Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson';s disease, and stroke. The Annals of Pharmacotherapy, 30 (12) , 1446-1451

Privitera,M., Kohler,C., Cahill,W., Yeh,H. S.  (1996). Postictal language dysfunction in patients with right or bilateral hemispheric language localization. Epilepsia, 37 (10) , 936-941

Arnold,L. M., Privitera,M. D.  (1996). Psychopathology and trauma in epileptic and psychogenic seizure patients. Psychosomatics, 37 (5) , 438-443

Privitera,M., Fincham,R., Penry,J., Reife,R., Kramer,L., Pledger,G., Karim,R.  (1996). Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology, 46 (6) , 1678-1683

Privitera,M.  (1995). Ictal verbal behaviour. Seizure : the journal of the British Epilepsy Association, 4 (3) , 245

Jooma,R., Yeh,H. S., Privitera,M. D., Gartner,M.  (1995). Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. Journal of neurosurgery, 83 (2) , 231-236

Shuren,J. E., Schefft,B. K., Yeh,H. S., Privitera,M. D., Cahill,W. T., Houston,W.  (1995). Repetition and the arcuate fasciculus. Journal of neurology, 242 (9) , 596-598

Jooma,R., Yeh,H. S., Privitera,M. D., Rigrish,D., Gartner,M.  (1995). Seizure control and extent of mesial temporal resection. Acta Neurochirurgica, 133 (1-2) , 44-49

Privitera,M. D., Treiman,D. M., Pledger,G. W., Sahlroot,J. T., Handforth,A., Linde,M. S., France,C. R., Cereghino,J. J., McCutchen,C. B., Wood,J. H.  (1994). Dezinamide for partial seizures: results of an n-of-1 design trial. Neurology, 44 (8) , 1453-1458

Privitera,M., Hoffman,M., Moore,J. L., Jester,D.  (1994). EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy research, 18 (2) , 155-166

Blisard,K. S., Fagin,K., Falivena,P., Privitera,M. D., Olejniczak,P., Harrington,D. A., Taylor,K. L., Scremin,O. U.  (1994). Experimental seizures in the frog (Rana pipiens). Epilepsy research, 17 (1) , 13-22

Privitera,M. D.  (1993). Clinical rules for phenytoin dosing. The Annals of Pharmacotherapy, 27 (10) , 1169-1173

Jacobson,G. P., Newman,C. W., Privitera,M., Grayson,A. S.  (1991). Differences in superficial and deep source contributions to middle latency auditory evoked potential Pa component in normal subjects and patients with neurologic disease. Journal of the American Academy of Audiology, 2 (1) , 7-17

Privitera,M. D., Morris,G. L., Gilliam,F.  (1991). Postictal language assessment and lateralization of complex partial seizures. Annals of Neurology, 30 (3) , 391-396

Yeh,H. S., Privitera,M. D.  (1991). Secondary epileptogenesis in cerebral arteriovenous malformations. Archives of Neurology, 48 (11) , 1122-1124

Privitera,M. D., Quinlan,J. G., Yeh,H. S.  (1990). Interictal spike detection comparing subdural and depth electrodes during electrocorticography. Electroencephalography and clinical neurophysiology, 76 (5) , 379-387

Liwnicz,B. H., Leach,J. L., Yeh,H. S., Privitera,M.  (1990). Pericyte degeneration and thickening of basement membranes of cerebral microvessels in complex partial seizures: electron microscopic study of surgically removed tissue. Neurosurgery, 26 (3) , 409-420

Jacobson,G. P., Privitera,M., Neils,J. R., Grayson,A. S., Yeh,H. S.  (1990). The effects of anterior temporal lobectomy (ATL) on the middle-latency auditory evoked potential (MLAEP). Electroencephalography and clinical neurophysiology, 75 (3) , 230-241

Crutcher,K. A., Privitera,M.  (1989). Axonal regeneration on mature human brain tissue sections in culture. Annals of Neurology, 26 (4) , 580-583

Privitera,M. D., Homan,R. W., Ludden,T. M., Peck,C. C., Vasko,M. R.  (1989). Clinical utility of a Bayesian dosing program for phenytoin. Therapeutic drug monitoring, 11 (3) , 285-294

Privitera,M. D.  (1989). Dosing accuracy of antiepileptic drug regimens as determined by serum concentrations in outpatient epilepsy clinic patients. Therapeutic drug monitoring, 11 (6) , 647-651

Kim, Kwang Ki; Privitera, Michael D; Szaflarski, Jerzy P  (2011). Lessons learned from a comparison of language localisation using fMRI and electrocortical mapping: case studies of neocortical epilepsy patients. Epileptic disorders : international epilepsy journal with videotape, 13 (4) , 368-74More Information

Kim, Kwang Ki; Karunanayaka, Prasanna; Privitera, Michael D; Holland, Scott K; Szaflarski, Jerzy P  (2011). Semantic association investigated with functional MRI and independent component analysis. Epilepsy & behavior : E&B, 20 (4) , 613-22More Information

Szaflarski, Jerzy P; DiFrancesco, Mark; Hirschauer, Thomas; Banks, Christi; Privitera, Michael D; Gotman, Jean; Holland, Scott K  (2010). Cortical and subcortical contributions to absence seizure onset examined with EEG/fMRI. Epilepsy & behavior : E&B, 18 (4) , 404-13More Information

Donnelly, Kiely M; Schefft, Bruce K; Howe, Steven R; Szaflarski, Jerzy P; Yeh, Hwa-shain; Privitera, Michael D  (2010). Moderating effect of optimism on emotional distress and seizure control in adults with temporal lobe epilepsy. Epilepsy & behavior : E&B, 18 (4) , 374-80More Information

Ramirez, Maya J; Schefft, Bruce K; Howe, Steven R; Hovanitz, Christine; Yeh, Hwa-shain; Privitera, Michael D  (2010). The effects of perceived emotional distress on language performance in intractable epilepsy. Epilepsy & behavior : E&B, 18 (1-2) , 64-73More Information

Szaflarski, Jerzy P; Lindsell, Christopher J; Zakaria, Tarek; Banks, Christi; Privitera, Michael D  (2010). Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response. Epilepsy & behavior : E&B, 17 (4) , 525-30More Information

Black, Leah Chapman; Schefft, Bruce K; Howe, Steven R; Szaflarski, Jerzy P; Yeh, Hwa-shain; Privitera, Michael D  (2010). The effect of seizures on working memory and executive functioning performance. Epilepsy & behavior : E&B, 17 (3) , 412-9More Information

Potter, Jennifer Loyden; Schefft, Bruce K; Beebe, Dean W; Howe, Steven R; Yeh, Hwa-Shain; Privitera, Michael D  (2009). Presurgical neuropsychological testing predicts cognitive and seizure outcomes after anterior temporal lobectomy. Epilepsy & behavior : E&B, 16 (2) , 246-53More Information

McNally, Kelly A; Schefft, Bruce K; Szaflarski, Jerzy P; Howe, Steven R; Yeh, Hwa-Shain; Privitera, Michael D  (2009). Application of signal detection theory to verbal memory testing to distinguish patients with psychogenic nonepileptic seizures from patients with epileptic seizures. Epilepsy & behavior : E&B, 14 (4) , 597-603More Information

Griffith, Nathan M; Smith, Kristen M; Schefft, Bruce K; Szaflarski, Jerzy P; Privitera, Michael D  (2008). Optimism, pessimism, and neuropsychological performance across semiology-based subtypes of psychogenic nonepileptic seizures. Epilepsy & behavior : E&B, 13 (3) , 478-84More Information

Privitera, Michael DGeneric antiepileptic drugs: current controversies and future directions. Epilepsy currents / American Epilepsy Society, 8 (5) , 113-7More Information

Schefft, Bruce K; Dulay, Mario F; Fargo, Jamison D; Szaflarski, Jerzy P; Yeh, Hwa-shain; Privitera, Michael D  (2008). The use of self-generation procedures facilitates verbal memory in individuals with seizure disorders. Epilepsy & behavior : E&B, 13 (1) , 162-8More Information

Vannest, Jennifer; Szaflarski, Jerzy P; Privitera, Michael D; Schefft, Bruce K; Holland, Scott K  (2008). Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy & behavior : E&B, 12 (3) , 410-8More Information

Fargo, Jamison D; Schefft, Bruce K; Szaflarski, Jerzy P; Howe, Steven R; Yeh, Hwa-Shain; Privitera, Michael D  (2008). Accuracy of clinical neuropsychological versus statistical prediction in the classification of seizure types. The Clinical neuropsychologist, 22 (2) , 181-94More Information

Ramirez, Maya J; Schefft, Bruce K; Howe, Steven R; Hwa-Shain, Yeh; Privitera, Michael D  (2008). Interictal and postictal language testing accurately lateralizes language dominant temporal lobe complex partial seizures. Epilepsia, 49 (1) , 22-32More Information

Szaflarski, Jerzy P; Holland, Scott K; Jacola, Lisa M; Lindsell, Christopher; Privitera, Michael D; Szaflarski, Magdalena  (2008). Comprehensive presurgical functional MRI language evaluation in adult patients with epilepsy. Epilepsy & behavior : E&B, 12 (1) , 74-83More Information

Griffith, Nathan M; Szaflarski, Jerzy P; Schefft, Bruce K; Isaradisaikul, David; Meckler, Jason M; McNally, Kelly A; Privitera, Michael D  (2007). Relationship between semiology of psychogenic nonepileptic seizures and Minnesota Multiphasic Personality Inventory profile. Epilepsy & behavior : E&B, 11 (1) , 105-11More Information

Fargo, Jamison D; Schefft, Bruce K; Kent, Glenn P; Szaflarski, Jerzy P; Privitera, Michael D; Yeh, Hwa-Shain  (2007). The prevalence of seizure types among individuals referred for phase I neuropsychological assessment: demographic and neuropsychological characteristics. The Clinical neuropsychologist, 21 (3) , 442-55More Information

Testa, S Marc; Schefft, Bruce K; Szaflarski, Jerzy P; Yeh, Hwa-Shain; Privitera, Michael D  (2007). Mood, personality, and health-related quality of life in epileptic and psychogenic seizure disorders. Epilepsia, 48 (5) , 973-82More Information

Szaflarski, Jerzy P; Meckler, Jason M; Szaflarski, Magdalena; Shutter, Lori A; Privitera, Michael D; Yates, Stephen L  (2007). Levetiracetam use in critically ill patients. Neurocritical care, 7 (2) , 140-7More Information

Kent, Glenn P; Schefft, Bruce K; Howe, Steven R; Szaflarski, Jerzy P; Yeh, Hwa-Shain; Privitera, Michael D  (2006). The effects of duration of intractable epilepsy on memory function. Epilepsy & behavior : E&B, 9 (3) , 469-77More Information

Szaflarski, Magdalena; Szaflarski, Jerzy P; Privitera, Michael D; Ficker, David M; Horner, Ronnie D  (2006). Racial/ethnic disparities in the treatment of epilepsy: what do we know? What do we need to know?. Epilepsy & behavior : E&B, 9 (2) , 243-64More Information

Szaflarski, Magdalena; Meckler, Jason M; Privitera, Michael D; Szaflarski, Jerzy P  (2006). Quality of life in medication-resistant epilepsy: the effects of patient's age, age at seizure onset, and disease duration. Epilepsy & behavior : E&B, 8 (3) , 547-51More Information

Welty, Timothy E; Faught, Edward; Privitera, Michael D  (2006). Step therapy is not appropriate for antiepileptic drugs. Journal of managed care pharmacy : JMCP, 12 (3) , 269-70; author reply

Arroyo, S; Dodson, W E; Privitera, M D; Glauser, T A; Naritoku, D K; Dlugos, D J; Wang, S; Schwabe, S K; Twyman, R E  (2005). Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta neurologica Scandinavica, 112 (4) , 214-22More Information

Griffith, Nathan M; Szaflarski, Jerzy P; Szaflarski, Magdalena; Kent, Glenn P; Schefft, Bruce K; Howe, Steven R; Privitera, Michael D  (2005). Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II. Epilepsy & behavior : E&B, 7 (2) , 266-72More Information

Fargo, Jamison D; Schefft, Bruce K; Dulay, Mario F; Privitera, Michael D; Yeh, Hwa-Shain  (2005). Confrontation naming in individuals with temporal lobe epilepsy: a quantitative analysis of paraphasic error subtypes. Neuropsychology, 19 (5) , 603-11More Information

Dulay, Mario F; Schefft, Bruce K; Fargo, Jamison D; Privitera, Michael D; Yeh, Hwa-Shain  (2004). Severity of depressive symptoms, hippocampal sclerosis, auditory memory, and side of seizure focus in temporal lobe epilepsy. Epilepsy & behavior : E&B, 5 (4) , 522-31More Information

Szaflarski, Jerzy P; Holland, Scott K; Schmithorst, Vincent J; Dunn, R Scott; Privitera, Michael D  (2004). High-resolution functional MRI at 3T in healthy and epilepsy subjects: hippocampal activation with picture encoding task. Epilepsy & behavior : E&B, 5 (2) , 244-52More Information

Fargo, Jamison D; Schefft, Bruce K; Szaflarski, Jerzy P; Dulay, Mario F; Testa, S Marc; Privitera, Michael D; Yeh, Hwa-Shain  (2004). Accuracy of self-reported neuropsychological functioning in individuals with epileptic or psychogenic nonepileptic seizures. Epilepsy & behavior : E&B, 5 (2) , 143-50More Information

Tang, Y; Glauser, T A; Gilbert, D L; Hershey, A D; Privitera, M D; Ficker, D M; Szaflarski, J P; Sharp, F R  (2004). Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta neurologica Scandinavica, 109 (3) , 159-68

Privitera, Michael D; Welty, Timothy  (2004). Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction. Neurology, 62 (1) , 161; author reply 16

Privitera, Michael D  (2003). Phase IV trials: a wolf in sheep's clothing?. The Annals of pharmacotherapy, 37 (5) , 741-3

Schefft, Bruce K; Marc Testa, S; Dulay, Mario F; Privitera, Michael D; Yeh, Hwa-Shain  (2003). Preoperative assessment of confrontation naming ability and interictal paraphasia production in unilateral temporal lobe epilepsy. Epilepsy & behavior : E&B, 4 (2) , 161-8

Szaflarski, Jerzy P; Szaflarski, Magdalena; Hughes, Cindy; Ficker, David M; Cahill, William T; Privitera, Michael D  (2003). Psychopathology and quality of life: psychogenic non-epileptic seizures versus epilepsy. Medical science monitor : international medical journal of experimental and clinical research, 9 (4) , CR113-8

Abou-Khalil, B; Hemdal, Paula; Privitera, M D  (2003). An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure : the journal of the British Epilepsy Association, 12 (3) , 141-9

Privitera, M D; Brodie, M J; Mattson, R H; Chadwick, D W; Neto, W; Wang, S  (2003). Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta neurologica Scandinavica, 107 (3) , 165-75

Szaflarski, Jerzy P; Hughes, Cynthia; Szaflarski, Magdalena; Ficker, David M; Cahill, William T; Li, Maureen; Privitera, Michael D  (2003). Quality of life in psychogenic nonepileptic seizures. Epilepsia, 44 (2) , 236-42

Welty, Timothy E; Gidal, Barry E; Ficker, David M; Privitera, Michael D  (2002). Levetiracetam: a different approach to the pharmacotherapy of epilepsy. The Annals of pharmacotherapy, 36 (2) , 296-304

Privitera, M D; Welty, T E; Ficker, D M; Welge, J  (2002). Vagus nerve stimulation for partial seizures. Cochrane database of systematic reviews (Online) (1) , CD002896More Information

Ficker, D M; Shukla, R; Privitera, M D  (2001). Postictal language dysfunction in complex partial seizures: effect of contralateral ictal spread. Neurology, 56 (11) , 1590-2

Chaisewikul, R; Privitera, M D; Hutton, J L; Marson, A G  (2001). Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane database of systematic reviews (Online) (1) , CD001901More Information

Szaflarski, J P; Ficker, D M; Cahill, W T; Privitera, M D  (2000). Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology, 55 (10) , 1561-3

Morrell, M J; McLean, M J; Willmore, L J; Privitera, M D; Faught, R E; Holmes, G L; Magnus, L; Bernstein, P; Rose-Legatt,  (2000). Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group. Seizure : the journal of the British Epilepsy Association, 9 (4) , 241-8More Information

Privitera, M D; Yeh, H S; Blisard, K; Sanchez, N  (2000). Detection of epileptogenic focal cortical dysplasia by depth, not subdural electrodes. Neurosurgical review, 23 (1) , 49-51

Gidal, B E; Privitera, M D; Sheth, R D; Gilman, J T  (1999). Vigabatrin: a novel therapy for seizure disorders. The Annals of pharmacotherapy, 33 (12) , 1277-86

Privitera, ; Szaflarski,  (1999). Complex Partial Seizures in Adults. Current treatment options in neurology, 1 (4) , 323-338

Fleck, D E; Berch, D B; Shear, P K; Schefft, B K; Privitera, M D; Strakowski, S M  (1999). Directed forgetting deficits in patients with temporal lobe epilepsy: an information processing perspective. Journal of the International Neuropsychological Society : JINS, 5 (6) , 549-55

McLean, M J; Morrell, M J; Willmore, L J; Privitera, M D; Faught, R E; Holmes, G L; Magnus-Miller, L; Bernstein, P; Rose-Legatt, A  (1999). Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia, 40 (7) , 965-72

Privitera, M D  (1999). Evidence-based medicine and antiepileptic drugs. Epilepsia, 40 Suppl 5, S47-56

Akimura, T; Yeh, H S; Mantil, J C; Privitera, M D; Gartner, M; Tomsick, T A  (1999). Cerebral metabolism of the remote area after epilepsy surgery. Neurologia medico-chirurgica, 39 (1) , 16-25; discussion 25

Privitera, M D  (1997). Topiramate: a new antiepileptic drug. The Annals of pharmacotherapy, 31 (10) , 1164-73

Gidal, B E; Crismon, M L; Wagner, M L; Fagan, S C; Privitera, M D; Dalmady-Israel, C; Graves, N M  (1996). Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke. The Annals of pharmacotherapy, 30 (12) , 1446-51

Gidal, B E; Wagner, M L; Privitera, M D; Dalmady-Israel, C; Crismon, M L; Fagan, S C; Graves, N M  (1996). Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. The Annals of pharmacotherapy, 30 (11) , 1272-6

Arnold, L M; Privitera, M DPsychopathology and trauma in epileptic and psychogenic seizure patients. Psychosomatics, 37 (5) , 438-43

Shuren, J E; Schefft, B K; Yeh, H S; Privitera, M D; Cahill, W T; Houston, W  (1995). Repetition and the arcuate fasciculus. Journal of neurology, 242 (9) , 596-8

Jooma, R; Yeh, H S; Privitera, M D; Gartner, M  (1995). Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. Journal of neurosurgery, 83 (2) , 231-6More Information

Jooma, R; Yeh, H S; Privitera, M D; Rigrish, D; Gartner, M  (1995). Seizure control and extent of mesial temporal resection. Acta neurochirurgica, 133 (1-2) , 44-9

Privitera, M D; Strawsburg, R H  (1994). Electroencephalographic monitoring in the emergency department. Emergency medicine clinics of North America, 12 (4) , 1089-100

Privitera, M D; Treiman, D M; Pledger, G W; Sahlroot, J T; Handforth, A; Linde, M S; France, C R; Cereghino, J J; McCutchen, C B; Wood, J H  (1994). Dezinamide for partial seizures: results of an n-of-1 design trial. Neurology, 44 (8) , 1453-8

Blisard, K S; Fagin, K; Falivena, P; Privitera, M D; Olejniczak, P; Harrington, D A; Taylor, K L; Scremin, O U  (1994). Experimental seizures in the frog (Rana pipiens). Epilepsy research, 17 (1) , 13-22

Privitera, M D  (1993). Clinical rules for phenytoin dosing. The Annals of pharmacotherapy, 27 (10) , 1169-73

Yeh, H S; Privitera, M D  (1991). Secondary epileptogenesis in cerebral arteriovenous malformations. Archives of neurology, 48 (11) , 1122-4

Privitera, M D; Morris, G L; Gilliam, F  (1991). Postictal language assessment and lateralization of complex partial seizures. Annals of neurology, 30 (3) , 391-6More Information

Privitera, M D; Quinlan, J G; Yeh, H S  (1990). Interictal spike detection comparing subdural and depth electrodes during electrocorticography. Electroencephalography and clinical neurophysiology, 76 (5) , 379-87

Privitera, M D  (1989). Dosing accuracy of antiepileptic drug regimens as determined by serum concentrations in outpatient epilepsy clinic patients. Therapeutic drug monitoring, 11 (6) , 647-51

Privitera, M D; Homan, R W; Ludden, T M; Peck, C C; Vasko, M R  (1989). Clinical utility of a Bayesian dosing program for phenytoin. Therapeutic drug monitoring, 11 (3) , 285-94

Kay, Benjamin P; Holland, Scott K; Privitera, Michael D; Szaflarski, Jerzy P  (2014). Differences in paracingulate connectivity associated with epileptiform discharges and uncontrolled seizures in genetic generalized epilepsy. Epilepsia, 55 (2) , 256-63More Information

Knight, William A; Hart, Kimberly W; Adeoye, Opeolu M; Bonomo, Jordan B; Keegan, Shaun P; Ficker, David M; Szaflarski, Jerzy P; Privitera, Michael D; Lindsell, Christopher J  (2013). The incidence of seizures in patients undergoing therapeutic hypothermia after resuscitation from cardiac arrest. Epilepsy research, 106 (3) , 396-402More Information

Wilcox, Karen S; Dixon-Salazar, Tracy; Sills, Graeme J; Ben-Menachem, Elinor; White, H Steve; Porter, Roger J; Dichter, Marc A; Moshé, Solomon L; Noebels, Jeffrey L; Privitera, Michael D; Rogawski, Michael A  (2013). Issues related to development of new antiseizure treatments. Epilepsia, 54 Suppl 4, 24-34More Information

French, Jacqueline A; White, H Steve; Klitgaard, Henrik; Holmes, Gregory L; Privitera, Michael D; Cole, Andrew J; Quay, Ellinor; Wiebe, Samuel; Schmidt, Dieter; Porter, Roger J; Arzimanoglou, Alexis; Trinka, Eugen; Perucca, Emilio  (2013). Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia, 54 Suppl 4, 3-12More Information

Kaplan, Marcia J; Dwivedi, Alok K; Privitera, Michael D; Isaacs, Kelly; Hughes, Cynthia; Bowman, Michelle  (2013). Comparisons of childhood trauma, alexithymia, and defensive styles in patients with psychogenic non-epileptic seizures vs. epilepsy: Implications for the etiology of conversion disorder. Journal of psychosomatic research, 75 (2) , 142-6More Information

Szaflarski, Jerzy P; Kay, Benjamin; Gotman, Jean; Privitera, Michael D; Holland, Scott K  (2013). The relationship between the localization of the generalized spike and wave discharge generators and the response to valproate. Epilepsia, 54 (3) , 471-80More Information

Kay, Benjamin P; DiFrancesco, Mark W; Privitera, Michael D; Gotman, Jean; Holland, Scott K; Szaflarski, Jerzy P  (2013). Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy. Epilepsia, 54 (3) , 461-70More Information

Polak, Emily L; Privitera, Michael D; Lipton, Richard B; Haut, Sheryl R  (2012). Behavioral intervention as an add-on therapy in epilepsy: designing a clinical trial. Epilepsy & behavior : E&B, 25 (4) , 505-10More Information

Wulsin, Aynara C; Solomon, Matia B; Privitera, Michael D; Danzer, Steve C; Herman, James P  (2016). Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy. Physiology & behavior, 166, 22-31More Information

Privitera, Michael D; Welty, Timothy E; Gidal, Barry E; Diaz, Francisco J; Krebill, Ron; Szaflarski, Jerzy P; Dworetzky, Barbara A; Pollard, John R; Elder, Edmund J; Jiang, Wenlei; Jiang, Xiaohui; Berg, Michel  (2016). Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. The Lancet. Neurology, 15 (4) , 365-72More Information

Berg, Michel; Welty, Timothy E; Gidal, Barry E; Diaz, Francisco J; Krebill, Ron; Szaflarski, Jerzy P; Dworetzky, Barbara A; Pollard, John R; Elder, Edmund J; Jiang, Wenlei; Jiang, Xiaohui; Switzer, Regina D; Privitera, Michael D  (2017). Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. JAMA neurology, 74 (8) , 919-926More Information

Alsherbini, Khalid A; Plancher, Joao Mc-O?Neil; Ficker, David M; Foreman, Brandon P; Adeoye, Opeolu M; Ying, Jun; Privitera, Michael D  (2017). Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges in Coma-Incidence and Interrater Reliability of Continuous EEG After a Standard Stimulation Protocol: A Prospective Study. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 34 (4) , 375-380More Information

McKee, Heather R; Privitera, Michael D  (2017). Stress as a seizure precipitant: Identification, associated factors, and treatment options. Seizure, 44, 21-26More Information

Alsherbini, Khalid A; Metter, E Jeffrey; Foreman, Brandon P; Privitera, Michael D  (2019). Reply to: Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges in Coma Incidence and Interrater Reliability of Continuous EEG After a Standard Stimulation Protocol; Statistical Issue to Avoid Misdiagnosis and Mismanagement. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 36 (4) , 320-321More Information

1985 Wilder Penfield Fellow for Clinical Epilepsy from Epilepsy Foundation of America for project A Computer Assisted Phenytoin Dosing

1986 Competitive renewal of Wilder Penfield Fellowship for Clinical Epilepsy

1992-1996 Abstract reviewer, American Academy of Neurology, Epilepsy Section

1994 Contributing reviewer, University Hospitals Consortium Drug Monographs

1995 Elected to American Neurological Association

1996 Ad hoc reviewer, Drugs

1997 Co-Chair: American Academy of Neurology section Epilepsy: Antiepileptic Drugs

1997 Ad hoc reviewer: Expert opinion on investigational drugs

1997 Ad hoc reviewer: Medical Letter

1997 Resident teaching award, Department of Neurology

1997-2000 Course Director: Epilepsy I & II at American Academy of Neurology Annual Course

1996-2002 Editor, Epilepsy Quarterly

1991-present Ad hoc reviewer, Electroencephalography and Clinical Neurophysiology

1992-present Ad hoc reviewer, Annals of Pharmacotherapy

1993-present Editorial advisory board, Annals of Pharmacotherapy

1993-present Ad hoc reviewer, Epilepsia, Epilepsy Research, Annals of Neurology, Neurology, Lancet, New England Journal of Medicine, Expert Review of Neurotherapeutics Abstract Reviewer: American Academy of Neurology

2003-present Alpha Omega Alpha (elected)

2003-2008 Best Doctors in America

2004 Business Courier’s Health Care Hero Award

2004 Research proposal reviewer: The Israel Science Foundation

2005 Epilepsy Foundation: “King of Mardi Gras”

2006 National Health Service (UK) Health Technology Assessment Reviewer

2008 Nominated for Doctor’s Day Outstanding Medical Staff Award at University Hospital

1982-present American Academy of Neurology

1984-present American Epilepsy Society

1995-present American Neurological Association

2001-present Academy of Medicine of Cincinnati

2002-present Ohio State Medical Association

Academic - Stetson Building
Suite 2300
Cincinnati  Ohio, 45267-0525
Phone: 513-558-2968
Fax: 513-558-4887
michael.privitera@uc.edu